ArticleBMC endocrine disorders2026
The role of serum miR-28-5p in predicting diabetic retinopathy onset in type 2 diabetes.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis research investigates miR-28-5p in type 2 diabetes mellitus (T2DM), aiming to clarify its mechanistic role and clinical significance in the pathogenesis of diabetic retinopathy (DR).
methodsThe research enrolled 112 T2DM patients (including 58 non-DR (NDR) and 54 DR) and 72 healthy controls. The expression of miR-28-5p and RAP1B were assessed by quantitative reverse transcription polymerase chain reaction. Receiver operating characteristic curve was employed to determine the diagnostic value of miR-28-5p in DR. Cell proliferation and migration were determined using cell counting kit-8 assay and Transwell assay. Concentrations of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were quantified via enzyme-linked immunosorbent assay. The direct targeting of RAP1B by miR-28-5p was validated using a luciferase reporter assay. The correlation between their expression was evaluated using Pearson correlation analysis.
resultsIn serum and cell samples, miR-28-5p was upregulated, while RAP1B was downregulated. In patients with DR, miR-28-5p expression was negatively correlated with that of RAP1B. miR-28-5p had good diagnostic value for distinguishing DR from NDR, with an area under the curve of 0.891, achieving a sensitivity of 77.80% and a specificity of 93.10% at a cut-off value of 2.165. In high-glucose (HG)-treated cells, inhibition of miR-28-5p enhanced cell proliferation and migration, while reducing IL-6 and TNF-α levels. RAP1B was a target gene of miR-28-5p. Suppressing miR-28-5p upregulated RAP1B in HG-treated cells.
conclusionsmiR-28-5p contributes to DR pathology by directly targeting and downregulating RAP1B. It may serve as a potential diagnostic biomarker and promising therapeutic target for DR. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.